ClinicalTrials.gg
CompletedNCT03361176Updated May 9, 2019Results posted

Kybella With Triamcinolone

A Phase 4 interventional study of Injectable sodium deoxycholate and Injectable sodium deoxycholate with Triamcinolone acetate in Adiposity, sponsored by Goldman, Butterwick, Fitzpatrick and Groff. Completed at 2 sites in United States. Open to participants aged 18 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2019-05-09.

Sponsored by Goldman, Butterwick, Fitzpatrick and Groff · Phase 4, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
30
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Study summary

This study is to evaluate the efficacy, edema and pain associated with Kybella(TM) injections of the upper neck in the treatment of submental fat with varying low concentrations of triamcinolone acetonide plus low doses of lidocaine.

Read the detailed description

This is a two-site randomized, double-blind comparison trial of Kybella(TM) injections with or without triamcinolone acetate for the reduction of submental fat. 30 subjects will be enrolled into the trial (15 subjects per site). At each site, 5 will be randomized to receive Kybella(TM) injections alone whereas 10 will receive Kybella(TM) plus differing doses of triamcinolone acetate in the following way:

  1. Group 1 (5 patients per site): Kybella(TM) alone: 2 mg/cm2 of Kybella(TM) with 0.2 mL of 1% lidocaine with no epinephrine plus 0.2cc saline to the non-TMC group to maintain equal concentrations in each injection so that the final Kybella concentration per vial will be 10mg/1.2mls or 1.6mg per 0.2 cc injection point will be delivered in up to 50 injections spaced 1.0 cm apart at 0.2 mL/injection for a total maximal dose of up to 100 mg of SDOC.
  2. Group 2 (10 patients per site): Kybella(TM)+TMC at 1.0 mg/mL: 2.0 mL of 2 mg/cm2 of Kybella(TM) will be mixed with 0.2 mL of 10 mg/mL of triamcinolone acetate, 0.2 mL of 1% lidocaine with no epinephrine and then delivered in up to 50 injections spaced 1.0 cm apart at 0.2 mL/injection for a total dose of up to 100 mg of SDOC using a 30 gauge (or smaller) 0.5-inch needle. The final Kybella concentration per vial will be 10mg/1.2mls or 1.6mg per 0.2 cc injection point

The treatment area will be bounded superiorly by a line 1 cm inferior to the mandibular margin, laterally by the sternocleidomastoid muscles, and inferiorly by the hyoid bone. The subjects and evaluating investigator will be blinded to the treatment, thus maintaining double-blind status. By nature of the varying volumes of injection, the treating investigator will be unblinded to the treatment. A series of 3 injection sessions will be performed spaced 4 weeks apart. No lidocaine will be injected prior to injections to prevent further dilution of injected Kybella™ as it will be premixed with Kybella™. Chilling with cold will be the method of pain reduction for needle insertion.

Canfield Vectra 3D imaging will be performed at baseline and final visit (Appendix C) with analysis and calculation of volumetric changes performed at baseline and final visit. Photos will also be taken with the Intellistudio at all other visits. Follow up visits will be performed 3 and 5 days after each injection session to assess for side effect and tolerability profile. After the final injection session, additional follow up visits will be performed at days 90 and 180 to assess for efficacy. Subject weight will be recorded at baseline and at end of study.

02

Conditions studied

  • Adiposity

Browse trials for

03

In context

Obesity

11,556 studies on the registry are indexed under Obesity; 2,055 are open to participants now.

This study's enrollment of 30 is below the median of 67 across 9,036 interventional studies indexed under Obesity.

Browse Obesity studies →

Lead sponsor

Goldman, Butterwick, Fitzpatrick and Groff is the lead sponsor of 41 studies on the registry; 12 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Females or Males in good general health age 18 - 65 years of age
  2. Fitzpatrick skin types I-VI
  3. Must be willing to give and sign a HIPAA form and form
  4. Must be willing and able to comply with all study protocols and schedules
  5. Must have submental fat graded by the investigator as 2 or 3 using the Clinician-Reported Submental Fat Rating Scale (PR-SMFRS)
  6. Negative urine pregnancy test prior to each treatment (if applicable)
  7. Female patients will be either of non- defined as:

    7.1 Having no uterus 7.2 No menses for at least 12 months. Or; (WOCBP) women of childbearing potential must agree to use an effective method of during the course of the study, such as: 7.3 Oral contraceptive pill, injection, implant, patch, vaginal ring, intrauterine device 7.4 Intrauterine coil 7.5 Bilateral tubal ligation 7.6 Barrier method used with an additional form of contraception (e.g., sponge, spermicide or condom) 7.7 Abstinence (If practicing abstinence must agree to use barrier method described above (7.6) if becomes sexually active) 7.8 Vasectomized partner (must agree to use barrier method described above (7.6) if becomes sexually active with unvasectomized partner)

  8. Males must be willing to be clean shaven for all study visits
  9. The patient must have had a stable weight (no fluctuation of >15 pounds in a year), diet, and physical activity for the previous 6 months

Exclusion criteria

Exclusion Criteria:

  1. Pregnancy, currently breast feeding or planning pregnancy for the duration of the trial
  2. Any UNCONTROLLED systemic disease -a potential patient in whom therapy for a systemic disease is not yet stabilized will not be considered for entry into the study
  3. Treatment with botulinum toxin injections in the neck or chin area within 6 months before randomization
  4. Any Scars, unshaven hair, tattoos or jewelry on or near the proposed treatment area
  5. Significant history or current evidence of a medical, psychological or other disorder that, in the investigator's opinion, would preclude enrollment into the study
  6. An active dermatitis or open wound in the proposed treatment area
  7. An active bacterial, fungal, or viral infection in the proposed treatment area
  8. Pre-existing skin condition to the submental region that may confound evaluation or analysis, at investigator discretion
  9. Previously treated with subcutaneous sodium deoxycholate to the submental region
  10. Previously treated with focused ultrasound, radiofrequency, cryolipolysis or liposuction to the submental region within the previous 6 months
  11. Any other laser, light energy device, or chemical peel treatment to the submental region within the previous 3 months
  12. Pre-existing neurological or gastrointestinal condition leading to dysphagia, dysphonia or facial nerve palsy
  13. Pre-existing medical condition other than increased submental fat that may result in increased submental fullness such as but not limited to thyroid enlargement, goiter, cervical lymphadenopathy etc., at investigator discretion
  14. Must not have a planned fat reduction procedure of any variety to the submental region for the duration of the study
  15. Must not have planned significant alterations in diet or physical activity that may result in significant fluctuations in weight
  16. Current participation or participation within 30 days prior to the start of this study in a drug or other research study.
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Outcomes assessor)
Enrollment
30 participants (actual)

Study arms

  • Active comparator
    Control

    Control Group (5 patients per site): Kybella(TM) alone: 2 mg/cm2 of Kybella(TM) with 0.2 mL of 1% lidocaine with no epinephrine plus 0.2cc saline delivered in up to 50 injections per treatment session.

    Drug: Injectable sodium deoxycholate

  • Experimental
    w/ Triamcinolone

    Experimental Group (10 patients per site): Kybella(TM)+TMC at 1.0 mg/mL: 2.0 mL of 2 mg/cm2 of Kybella(TM) will be mixed with 0.2 mL of 10 mg/mL of triamcinolone acetate and 0.2 mL of 1% lidocaine with no epinephrine delivered in up to 50 injections per treatment session.

    Combination Product: Injectable sodium deoxycholate with Triamcinolone acetate

Interventions

  • DrugDeoxycholic AcidStudies of Deoxycholic AcidDeoxycholic Acid pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Kybella(TM) alone: 2 mg/cm2 of Kybella(TM) with 0.2 mL of 1% lidocaine with no epinephrine plus 0.2cc saline to the non-TMC group to maintain equal concentrations in each injection so that the final Kybella concentration per vial will be 10mg/1.2mls or 1.6mg per 0.2 cc injection point will be delivered in up to 50 injections spaced 1.0 cm apart at 0.2 mL/injection for a total maximal dose of up to 100 mg of SDOC.

    Also known as: Kybella

  • Combination productInjectable sodium deoxycholate with Triamcinolone acetate

    Kybella(TM)+TMC at 1.0 mg/mL: 2.0 mL of 2 mg/cm2 of Kybella(TM) will be mixed with 0.2 mL of 10 mg/mL of triamcinolone acetate, 0.2 mL of 1% lidocaine with no epinephrine and then delivered in up to 50 injections spaced 1.0 cm apart at 0.2 mL/injection for a total dose of up to 100 mg of SDOC using a 30 gauge (or smaller) 0.5-inch needle. The final Kybella concentration per vial will be 10mg/1.2mls or 1.6mg per 0.2 cc injection point

    Also known as: Kybella with Triamcinolone Acetate

06

What researchers measure

Primary outcomes

  1. Change in Clinician-Reported Submental Fat Rating Scale

    Change in efficacy will be measured from Baseline to 90 days post final treatment using a 5-point Clinician-Reported Submental Fat Rating Scale ranging from Absent (score of 0) to Extreme submental convexity (score of 4)

    Time frame: 90 Days from Baseline

Secondary outcomes

  1. Change in Clinician-Reported Submental Laxity Rating Scale

    Laxity will be compared between treatment groups at each post-treatment time point through Day 90 using a 5-Point Clinician Evaluation of Side Effects Scale ranging from None (score of 0) to Severe (score of 4).

    Time frame: 90 days from baseline

  2. Subject Satisfaction Rating Scale

    Satisfaction will be compared between treatment groups at each post-treatment time point through Day 180 using a 7-point satisfaction scale rating from extremely dissatisfied (score of 0) to extremely satisfied (score of 6).

    Time frame: Post-treatment to Day 180

07

Results

Posted May 9, 2019

Participant flow

Participant flow — Overall Study
MilestoneControlw/ Triamcinolone
Started1020
Completed915
Not completed15
Withdrew: Lost to follow-up12
Withdrew: Adverse event02
Withdrew: Withdrawal by subject01

Outcome measures

PrimaryChange in Clinician-Reported Submental Fat Rating Scale

Change in efficacy will be measured from Baseline to 90 days post final treatment using a 5-point Clinician-Reported Submental Fat Rating Scale ranging from Absent (score of 0) to Extreme submental convexity (score of 4)

Time frame:
90 Days from Baseline
Reported as:
Count of participants · Participants
Change in Clinician-Reported Submental Fat Rating Scale
ParticipantsControlw/ Triamcinolone
2-point improvement54
1-point improvement56
no improvement05
lost to follow up/withdrew from study05
SecondaryChange in Clinician-Reported Submental Laxity Rating Scale

Laxity will be compared between treatment groups at each post-treatment time point through Day 90 using a 5-Point Clinician Evaluation of Side Effects Scale ranging from None (score of 0) to Severe (score of 4).

Time frame:
90 days from baseline
Reported as:
Count of participants · Participants
Change in Clinician-Reported Submental Laxity Rating Scale
ParticipantsControlw/ Triamcinolone
2-point improvement32
1-point improvement24
no improvement59
lost to follow up/withdrew from study05
SecondarySubject Satisfaction Rating Scale

Satisfaction will be compared between treatment groups at each post-treatment time point through Day 180 using a 7-point satisfaction scale rating from extremely dissatisfied (score of 0) to extremely satisfied (score of 6).

Time frame:
Post-treatment to Day 180
Reported as:
Count of participants · Participants
Subject Satisfaction Rating Scale
ParticipantsControlw/ Triamcinolone
extremely satisfied17
satisfied71
slightly satisfied01
neither satisfied nor dissatisfied03
slightly dissatisfied03
dissatisfied10
extremely dissatisfied00
lost to follow up/withdrew from study15

Adverse events

Collected over Adverse event data were collected over 180 days.. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
w/ Triamcinolone0/20 (0%)0/20 (0%)1/20 (5%)
Control0/10 (0%)0/10 (0%)0/10 (0%)
Most frequent other events
Most frequent other events
Eventw/ TriamcinoloneControl
ErosionSkin and subcutaneous tissue disorders1/200/10
Neck pain secondary to motor vehicle accidentMusculoskeletal and connective tissue disorders1/200/10

Baseline characteristics

Age, Categorical
Age, Categorical(Participants)Controlw/ TriamcinoloneTotal
<=18 years000
Between 18 and 65 years102030
>=65 years000
Age, Continuous
Age, Continuous(years)Controlw/ TriamcinoloneTotal
Mean46.2 (29 to 62)46.55 (28 to 63)46.38 (28 to 63)
Sex: Female, Male
Sex: Female, Male(Participants)Controlw/ TriamcinoloneTotal
Female101828
Male022
Sex: Female, Male
Sex: Female, Male(Participants)Controlw/ TriamcinoloneTotal
Female101828
Male022
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Controlw/ TriamcinoloneTotal
American Indian or Alaska Native000
Asian011
Native Hawaiian or Other Pacific Islander000
Black or African American000
White101929
More than one race000
Unknown or Not Reported000
Region of Enrollment
Region of Enrollment(participants)Controlw/ TriamcinoloneTotal
United States102030
08

Study locations

2 sites
  • West Dermatology Research Center
    San Diego, California 92121, United States
  • Maryland Dermatology Laser, Skin and Vein Institute
    Hunt Valley, Maryland 21030, United States
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Mar 2018 to primary completion in Oct 2018, 6 months.

Results were first posted in May 2019, 6 months after primary completion.

Of 190 non-industry phase 4 interventional studies under Obesity, half reached primary completion within 32 months of starting (the median), counting those still running; a quarter within 15 and three quarters within 52. This study's 6 months is below that.

Counting every sponsor, half of 210 studies reached it within 31 months; a quarter within 15 and three quarters within 51.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 21, 2017
First posted
Dec 4, 2017
StartActual
Mar 26, 2018
Primary completionActual
Oct 12, 2018
CompletionActual
Dec 18, 2018
Results first posted
May 9, 2019
Last update
May 9, 2019
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 9, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03361176
Lead sponsor
Goldman, Butterwick, Fitzpatrick and Groff
Collaborators
Allergan, Maryland Laser Skin and Vein Institute
Responsible party
Sponsor
First posted
Dec 4, 2017
Start date
Mar 26, 2018
Primary completion
Oct 12, 2018
Completion
Dec 18, 2018
Results posted
May 9, 2019
Last update
May 9, 2019

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion